

Special Issue

Childhood Acute Lymphoblastic Leukemia

Message from the Guest Editor

Childhood Acute Lymphoblastic Leukemia (ALL) is the most prevalent pediatric malignancy, representing approximately 75% to 80% of childhood leukemias and around 25% of cancers in children under 15 years of age. There are two types: B-cell precursor ALL (B-ALL), constituting about 85% of cases, and T-cell ALL (T-ALL), which accounts for approximately 15%.

The advancements of precision treatment underscore the shift toward personalized medicine, improving survival rates while reducing long-term treatment-related toxicities. Continued research into the genetic and immunologic landscape of ALL holds the potential to further transform diagnostic and therapeutic strategies for this complex pediatric malignancy. This Special Issue aims to showcase research articles that advance the clinical and scientific knowledge of childhood ALL.

More information for submission, please scan the QR code on the right.

Guest Editor

Dr. Noriko Satake

Department of Pediatrics, UC Davis School of Medicine, Sacramento, CA, USA

Deadline for manuscript submissions

28 February 2026



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/229192

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)